Eric Little is Co-founder & CEO of LeapAnlysis. He received his Ph.D. in Philosophy and Cognitive Science in 2002 from the University at Buffalo, State University of New York. He has worked in both academia as a professor in several fields, as well as held multiple management positions in the software development industry. Dr. Little is a recognized expert in semantic technology, Big Data, analytics applications, and formal ontology. Dr. Little has designed and helped to implement semantic technologies and analytics for use in various applied domains including: biomedicine, medical device manufacturing, medical fraud, waste and abuse detection, pharmaceuticals, medical management, threat prediction/mitigation, disaster management, national defense/intelligence, steel production and petrochemicals.
AI and Data Sciences Showcase:
LeapAnalysis allows people to quickly and cheaply integrate data of virtually any kind together on-the-fly using virtualized semantics and machine learning across fully idsconnected data sources. No ETL pipelines & no migration needed. With LA people can "Embrace Your Data Silos".
A New Era of Pragmatic AI: Connecting Virtualized Semantics And Machine Learning
This talk will describe some of the background approaches to data integration (data warehouses & lakes) and why they have met serious challenges to date. We will discuss traditional approaches to AI solutions and look to the horizon in order to understand how to build systems that look and feel more like real human intelligence - ones that can leverage both legacy systems (relational systems, file stores, etc.) along with new types of data (image, video, text analysis, etc.). We call this approach Pragmatic AI and it is the basis for our LeapAnalysis product, which provides unprecedented capabilities to run search & analysis over fully federated data sources using combined semantic technologies and machine learning.
The PMWC 2020 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.